2026-04-29T02:37:51Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/225162024-11-28T17:53:06Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967
Repisalud
author
Alonso, Vicente
author
Escudero, Pilar
author
Fernandez-Martos, Carlos
author
Salud, Antonia
author
Mendez, Miguel
author
Gallego, Javier
author
Rodriguez, Jose-R
author
Martin-Richard, Marta
author
Fernandez-Plana, Julen
author
Manzano, Hermini
author
Mendez, Jose-Carlos
author
Zanui, Monserrat
author
Falcó, Esther
author
Gil-Raga, Mireia
author
Rojo, Federico
author
Cuatrecasas, Miriam
author
Feliu, Jaime
author
Garcia-Albeniz, Xabier
author
Maurel, Joan
2024-09-06T09:53:37Z
2024-09-06T09:53:37Z
2018-07
Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J, et al. Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. Neoplasia. 2018 Jul;20(7):678-86. Epub 2018 May 26.
1476-5586
http://hdl.handle.net/20.500.13003/17280
https://hdl.handle.net/20.500.12105/22516
29842993
10.1016/j.neo.2018.05.004
Neoplasia
2-s2.0-85047475405
436235300004
L2000801160
INTRODUCTION: The coexpression of pIGF-1R and MMP-7 (double-positive phenotype, DP) correlates with poor overall survival (OS) in KRAS wild-type (WT) (exon 2) metastatic colorectal cancer (mCRC) patients treated with irinotecan-cetuximab in second/third line. METHODS: We analyzed two prospective biomarker design trials of newly diagnosed RAS-WT mCRC patients treated with panitumumab-FOLFOX6 (PULSE trial; NCT01288339) or cetuximab plus either FOLFOX6/FOLFIRI (POSIBA trial; NCT01276379). The main exposure was DP phenotype (DP/ non-DP), as assessed by two independent pathologists. DP cases were defined by immunohistochemistry as N70% expression of moderate or strong intensity for both MMP-7 and pIGF-1R. Primary endpoint: progression-free survival (PFS); secondary endpoints: OS and response rate. PFS and OS were adjusted by baseline characteristics using multivariate Cox models. RESULTS: We analyzed 67 patients (30 non-DP, 37 DP) in the PULSE trial and 181 patients in the POSIBA trial (158 non-DP, 23 DP). Response rates and PFS were similar between groups in both studies. DP was associated with prolonged OS in PULSE (adjusted HR: 0.23; 95% CI: 0.11-0.52; P =. 0004) and with shorter OS in POSIBA (adjusted HR: 1 .67; 95% CI: 0.96-2.90; P =. 07). CONCLUSION: A differential effect of anti-EGFRs on survival by DP phenotype was observed. Panitumumab might be more beneficial for RAS-WT mCRC patients with DP phenotype, whereas cetuximab might improve OS in non-DP.
eng
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
research article